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Background
Increasing demand for compounded cytostatics has forced Danish hospital pharmacies to develop solutions which support effective work flow in decentralized and future centralized production units. One way to optimize the logistics is stock holding of compounded cytostatics for 1-3 months. This requires documentation of extended shelf lives of the compounded products.
Objective
The aim was to bring a survey of the shelf lives and the usefulness of the information stated in section 6.3 in the SPC's for 13 selected compounded cytostatics.
Materials and methods
The SPC's was identified on www.produktresume.dk and www.ema.europa.eu the 5'th of May 2011.
Results
For the 13 cytostatics 150 SPC's were identified. 
discussion
The longest shelf life identified for compounded cytostatics was 28 days for Doxorubicin, Epirubicine, Gemcitabine and Irinotecan. Great variation between the minimum-and maximum shelf lives for the same drug substance between different producers was observed. The biggest discrepancy occurred for Epirubicin with a minimum shelf life was "use immediately after compounding" and a maximum shelf life of 28 days after compounding. Table 2 shows that 24% of all the SPC's do not state shelf live for the compounded product, but only for the originalor reconstituted product.
Other observations were that besides few exceptions the concentration interval of which the shelf lives can be applied is not stated in the SPC's, and also consistent terminology in the SPC's is lacking.
